OBJECTIVE: To systematically review the efficacy of Silybin capsules in the treatment of hepatitis. METHODS: Randomized controlled trials on Silybin capsules in the treatment of hepatitis（the research group was given Silybin capsules alone

while the control group was treated with a regimen other than Silybin capsules） were retrieved from Embase

CNKI and other domestic and overseas database from the establishment of the database to Feb. 2022. After screening literature and assessing the risk of bias

Meta-analysis was performed by using RevMan 5.3 software. RESULTS: A total of 6 randomized controlled trials including 450 patients were enrolled

with 250 cases in the research group and 200 cases in the control groups

respectively. Results of analysis showed that patients in the research group treated with Silybin capsules had significantly better overall effective rate（OR=3.20

95%CI=1.82-5.62

P<0.000 1）

remission rate of poor appetite（OR=5.25

95%CI=2.77-9.94

P<0.000 01）

remission rate of fatigue（OR=2.73

95%CI=1.65-4.52

P<0.000 1）

remission rate of liver discomfort（OR=5.62

95%CI=2.90-10.90

P<0.000 01）

alanine aminotransferase level（MD=-13.46

95%CI=-24.02--2.90

P=0.01） and aspartate aminotransferase level（MD=-9.77

95%CI=-14.68--4.86

P<0.000 1） than those of the control group with other therapeutic regimens

with statistically significant differences. CONCLUSIONS: The available evidence indicated that the application of silymarin capsules alone in the treatment of hepatitis has a significant advantage over the control regimens in terms of efficacy. Due to the number and quality of the selected studies

the above findings need to be validated in more high-quality randomized controlled trials.